In SAFE-PCI trial, we evaluated if SGLT2i (empagliflozin) prevents CI-AKI among T2D patients undergoing elective PCI, as expressed by blood levels of biomarkers NGAL and creatinine. The gene discussed is LCN2; the disease is acute kidney injury.